Drug Trial Radar · NCT01345669
LUX-Head&Neck 2: A Phase III Trial of Afatinib (BIBW 2992) Versus Placebo for the Treatment of Head and Neck Squamous Cell Cancer After Treatment With Chemo-radiotherapy
Last checked: Nov 19, 2026Latest source record: Dec 7, 2017 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Terminated
Enrollment
617
Actual
Start
Oct 17, 2011
Primary completion
Sep 12, 2016
Study completion Sep 12, 2016
Sponsor
- Lead sponsor
- Boehringer IngelheimBoehringer Ingelheim
- Sponsor type
- Industry
- First posted
- May 2, 2011
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This randomised, double-blind phase III trial will be performed in patients with head and neck squamous cell carcinoma (HNSCC). The objectives of the trial are to compare the efficacy and safety of afatinib (BIBW 2992) with placebo as adjuvant therapy to patients who have received definitive chemo-radiotherapy.
Conditions
- Head and Neck Neoplasms
Interventions
PlaceboDrug
Once daily
AfatinibDrug
Once daily
Primary outcomes
What the sponsor says the trial is designed to measure.
- Disease Free Survival (DFS)Time frame: Up to 5 years
Locations
162 sites in 29 countries. Site status is shown where the registry gives one.
1200.131.00171 Boehringer Ingelheim Investigational Site
Little Rock, Arkansas
1200.131.00181 Boehringer Ingelheim Investigational Site
Orange, California
1200.131.00177 Boehringer Ingelheim Investigational Site
Aurora, Colorado
1200.131.00185 Boehringer Ingelheim Investigational Site
New Haven, Connecticut
1200.131.00173 Boehringer Ingelheim Investigational Site
Baltimore, Maryland
1200.131.00176 Boehringer Ingelheim Investigational Site
Boston, Massachusetts
1200.131.00182 Boehringer Ingelheim Investigational Site
Omaha, Nebraska
1200.131.00175 Boehringer Ingelheim Investigational Site
Lebanon, New Hampshire
1200.131.00179 Boehringer Ingelheim Investigational Site
Stony Brook, New York
1200.131.00188 Boehringer Ingelheim Investigational Site
The Bronx, New York
1200.131.10200 Boehringer Ingelheim Investigational Site
Winston-Salem, North Carolina
1200.131.00172 Boehringer Ingelheim Investigational Site
Philadelphia, Pennsylvania
1200.131.00184 Boehringer Ingelheim Investigational Site
San Antonio, Texas
1200.131.00198 Boehringer Ingelheim Investigational Site
Spokane Valley, Washington
1200.131.00183 Boehringer Ingelheim Investigational Site
Wenatchee, Washington
1200.131.05451 Boehringer Ingelheim Investigational Site
Ciudad Autonoma de Bs As, Argentina
1200.131.05457 Boehringer Ingelheim Investigational Site
Córdoba, Argentina
1200.131.05458 Boehringer Ingelheim Investigational Site
San Miguel de Tucumán, Argentina
1200.131.05452 Boehringer Ingelheim Investigational Site
Santa Fe, Argentina
1200.131.05453 Boehringer Ingelheim Investigational Site
Villa Domínico, Argentina
1200.131.06151 Boehringer Ingelheim Investigational Site
Wooloongabba, Queensland, Australia
1200.131.04353 Boehringer Ingelheim Investigational Site
Leoben, Austria
1200.131.04357 Boehringer Ingelheim Investigational Site
Linz, Austria
1200.131.04355 Boehringer Ingelheim Investigational Site
Salzburg, Austria
1200.131.04351 Boehringer Ingelheim Investigational Site
Vienna, Austria
1200.131.04359 Boehringer Ingelheim Investigational Site
Vienna, Austria
1200.131.03259 Boehringer Ingelheim Investigational Site
Brussels, Belgium
1200.131.03256 Boehringer Ingelheim Investigational Site
Charleroi, Belgium
1200.131.03255 Boehringer Ingelheim Investigational Site
Hasselt, Belgium
1200.131.03253 Boehringer Ingelheim Investigational Site
Kortrijk, Belgium
1200.131.03252 Boehringer Ingelheim Investigational Site
Liège, Belgium
1200.131.03254 Boehringer Ingelheim Investigational Site
Liège, Belgium
1200.131.03258 Boehringer Ingelheim Investigational Site
Namur, Belgium
1200.131.05554 Boehringer Ingelheim Investigational Site
Barretos, Brazil
1200.131.05555 Boehringer Ingelheim Investigational Site
Jaú, Brazil
1200.131.05557 Boehringer Ingelheim Investigational Site
Passo Fundo, Brazil
1200.131.05553 Boehringer Ingelheim Investigational Site
Porto Alegre, Brazil
1200.131.05551 Boehringer Ingelheim Investigational Site
São Paulo, Brazil
1200.131.05556 Boehringer Ingelheim Investigational Site
São Paulo, Brazil
1200.131.00152 Boehringer Ingelheim Investigational Site
Vancouver, British Columbia, Canada
Showing 40 of 162 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.